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(RFA)Abstract Background and objective: Venous ulcers are the most severe and debilitating sequel of
chronic venous insufﬁciency (CVI) and venous hypertension. They account for nearly 80% of all
lower extremity ulcers, with an overall prevalence of approximately 1–2%. The majority of these
patients are otherwise healthy individuals suffering from chronic ulceration during the most pro-
ductive period of life.
Objective: The aim of this work is to prospectively evaluate the using of foam sclerotherapy guided
by duplex ultrasound for injection of incompetent perforators to treat venous ulcer.
Materials and methods: This study was done on forty patients who were referred to management of
chronic venous ulcer. All patients were subjected to: pre-treatment evaluation, Ankle brachial pres-
sure index and venous duplex scan.
Results: As regards healing of leg ulcers in the 40 patients under this study: At 1, 3, and 6 months
after treatment: 5 ulcers (12.5%), 28 ulcers (70%) and 38 ulcers (95%), respectively had healed com-
pletely 3 ulcers had recurred (8%) during the follow up period.
Conclusions: Compared to surgical intervention, the relative freedom from serious complications
and its evident success, make this the ﬁrst line treatment for venous ulcer.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
Venous ulcers are the most severe and debilitating sequel of
chronic venous insufﬁciency (CVI) and venous hypertension
(1). They account for nearly 80% of all lower extremity ulcers,
with an overall prevalence of approximately 1–2% (1).
Approximately 1% of Europeans will develop chronic venous
ulcer (CVU) during their life time; the point prevalence of open
ulceration is estimated at 0.1% (2). The estimated cost of car-
ing for patients with venous ulcers exceeds $1.8 billion a year,
the majority of these patients are otherwise healthy individuals
Fig. 1 Foam produced by the tessari method.
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period of life (3). The treatment of CVU remains controversial
and outcomes are often disappointing, especially in the pres-
ence of (post-thrombotic) deep venous reﬂux (DVR) (4). Sur-
gery for venous ulcers is widely used in the UK but
recurrence may be expected in 25–50% of patients at 5 years
(5). Local wound care, including debridement, is standard
for venous ulcers. There are several different methods of
wound debridement, including autolytic, chemical and
mechanical debridement (6). More recently, it has been sug-
gested that foam sclerotherapy, which allows a smaller quan-
tity of sclerosant to cover a great surface area, might be
more effective and have fewer complications (7). At ﬁrst, foam
sclerotherapy was used to treat those limbs that had failed con-
ventional care. Then, as experience with the method increased,
it became clear that it should be used in treating patients as
soon as they were referred for care (8). The simplicity of the
treatment, compared to surgical intervention, the relative free-
dom from serious complications and its evident success, make
this the ﬁrst line treatment for venous ulcer (9).
2. Aim of the work
The aim of this prospective work was to evaluate the use of
foam sclerotherapy guided by duplex ultrasound for injection
of incompetent perforators to treat venous ulcer as regards
efﬁcacy for healing of ulcer, recurrence of ulcer and complica-
tions of the procedure.
3. Patients and method
This study was done on forty patients who were presented to
the vascular surgery out patient clinics from October 2011 to
December 2012. All patients were referred for management
of chronic venous ulcer. After a written informed consent
was obtained, the patients were subjected to the following:
 Pre-treatment evaluation by detailed history, physical
examination and CEAP clinical grading.
 Ankle brachial pressure index.
 Venous duplex scan was performed to determine the site of
incompetent perforators related to the ulcer.
 Written informed consent was obtained.
Exclusion criteria: the excluded patients from this study
were diabetics, recent deep venous thrombosis, pregnant,
known allergy to ethanolamine, those anticoagulated and
those with ankle brachial pressure index less than 0.8 and
ulcers.
*Pretreatment duplex ultrasound mapping: examinations
were performed in a standard manner. Patients were examined
standing with their weight on the contralateral limb and the leg
to be examined slightly bent with the heel on the ﬂoor to relax
the calf muscle while maintaining stability, with a sensosite
Micromaxx (sonosite Ltd., Hichin, Herts, UK) limited with a
10 MHZ transducer. The following venous segments were ins-
olated: Proximal and distal superﬁcial femoral vein; above and
below-knee popliteal vein, saphenofemoral and saphenopoplit-
eal junctions, the whole length of the great saphenous vein
(GSV) and the short saphenous vein (SSV). All veins were
examined for compressibility and patency. Reﬂux was inducedwith manual calf squeeze and was deﬁned as reverse ﬂow of
greater than 0.5 s. Incompetence of a perforating vein can be
determined by registering the reversal of ﬂow (directed to the
superﬁcial veins) longer than 0.4 s or by the size of the vein
at the fascial opening exceeding 3.5 mm, or by the presence
of both criteria. At the time of duplex scan, incompetent per-
forating veins were located in the areas of skin damage and ul-
cers, those connected with corona phlebectatica, or clusters of
varicose veins. This information is crucial for the development
of plan of sclerotherapy and for a decision on how to treat
each of the incompetent perforators.
Patient Positioning: for incompetent perforator veins on the
medial aspect of the leg, patient is placed in the supine position
with the treated leg lifting 20–40 cm above the couch level,
externally rotated at the hip and the knee is usually slightly
ﬂexed in order to relax all muscle groups. For short saphenous
and incompetent perforator veins on the posterior calf, the pa-
tient is positioned in the prone position with the foot sup-
ported by a pillow so that the knee is slightly ﬂexed.
Foam preparation: sclerosant foam was prepared by modi-
ﬁed tessari’s method using two 5 ml syringes. One syringe con-
tains 1 ml of ethanolamine oleate 5%, the other 4 ml of room
air. Syringes are connected by a three-way stopcock. Then
foam is obtained by cavitation by an average of 20 back and
forth passages from one syringe to the other. Stability of this
type of foam is correct for one to two minutes (Fig. 1).
*Technique of duplex guided injection of foam (Fig. 1): the
treatment process is directed towards eliminating all the
incompetent superﬁcial and perforator pathways by the foam
injection technique guided by duplex ultrasound to prevent
abnormal pressures and retrograde ﬂow from the deep to the
superﬁcial venous system. The technique is as follows:
(1) Imaging of the target vein through a transversal or lon-
gitudinal probe scan. Commonly 10 MHz transducer.
The location of the vein at the centre of the screen is
helpful to better managing the penetration of the needle
and to follow the foam distribution.
(2) Cleaning and disinfection of the selected area by alcohol
70%.
(3) Cannulation: a 20 G 44 mm butterﬂy is cannulating the
incompetent vein perforator. Correct placement could
be conﬁrmed by aspiration of non pulsatile venous
blood, ultrasound visualization of the needle tip and
ﬁnally injecting normal saline into the vein. The needle
is inserted close to the transducer tip along the sagittal
plane of the transducer. When the needle pierces the
Table 2 Sex distribution among the studied group.
Sex Number %
Male 30 75
Female 10 25
Total 40 100
Table 3 Patient distribution according to basic CEAP
classiﬁcation.
C E A P
C6 34 C6Ep 34 C6EpAs&p 34 C6EpAs&p Pr
40 16 C6Es 14 C6EsAs&p 14 C6EsAs&p Pr
2 C6 Es&p&d 2 C6EsAs&p&d Pr
Table 4 Complications of sclerotherapy.
Complication No. Legs
Phlebitis 4
Minor DVT 0
Drug reaction 0
Transient visual disturbance 0
Skin pigmentation 3
Skin necrosis 0
Extravasation 3
Pulmonary embolism 0
Sensation of chest tightness 2
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needle tip makes contact with the target vein, an inden-
tation will be seen on the vein wall then, little extra pres-
sure is done to pierce the vein wall to visualize the tip
within the lumen.
(4) A small volume of sclerosing foam is then injected about
1–4 ml and digital or transducer compression is per-
formed to prevent any spread of the foam towards the
deep venous system. Sometimes we use the pre-injection
internal compression technique by injecting 5 ml saline
around the perporator.
(5) 5- External compression by application of creep ban-
dage for one week followed by class II (25–35 mm/g)
graduated compression stocking.
(6) 6- Post injection instructions: patients were advised to
walk continuously for 15–20 min immediately after
treatment and then to walk for at least 45 min/day, for
2 days.
Follow up and outcome measures: the chosen outcome
measures were ulcer healing and complete occlusion or aboli-
tion of reﬂux. All patients were followed up at 7 days, 1, 3
and 6 months after treatment.
At ﬁrst visit the bandages were removed and a duplex was
performed to look speciﬁcally for DVT. In next follow up vis-
its we search for ulcer healing, repeat venous duplex examina-
tion and search for any complications.
4. Results
40 Patients of age ranging from 20 to 62 years (mean age of
43.4 years) presented to the out patient clinic from October
2011 to December 2012 with manifestation of venous ulcers,
were subjected to duplex ultrasound guided foam sclerother-
apy of incompetent perforator veins. Patients’ demographic
data are summarized in Tables 1 and 2.
The affected side: the affected left lower limbs were detected
in 27 patients (67.5%) while the affected right lower limb was
detected in 13 patients (32.5%).
The duration of patients’ complaint before evaluation ran-
ged from 2 to 7 years with mean duration of 2.87 years.
Aetiological ﬁndings: primary were found in 30 limbs
(75%) while secondary cases with history of deep venous
thrombosis was present in 10 patients (25%).
According to the clinical component of CEAP classiﬁcation
our patients were belonging to C6Ep,s As,p,d Pr,o and they were
classiﬁed using these criteria as in Table 3.Table 1 Age incidence.
Age group No. of patients %
20 to <25 2 5
25 to <30 2 5
30 to <35 3 7.5
35 to <40 8 20
40 to <45 6 15
45 to <50 10 25
50 to <55 6 15
55 to <60 1 2.5
60 to <65 2 5
Total 40 100The total volume of ethanolamine oleate 5% used for com-
pletion of all treatments of foam sclerotherapy ranges from 2
to 25 mL, depending on the size of the incompetent perforators
and number of sessions applied.
4.1. Post sclerotherapy complications
(a) Early complications: detected in ﬁve patients. Two
patients had sensation of chest tightness and they were
treated by intravenous short acting corticosteroids and
bronchodilators, and three patients had extravasation
of foam during injection and redirection of the needle
tip before recontinuation of foam injection.
(b) Late complications: detected in seven patients, four of
them develop superﬁcial thrombophebitis evident by
local erythema and oedema conﬁrmed by increased ech-
ogenecity surrounding the treated site on duplex scan-
ning and they were treated by local application of anti
inﬂammatory and hygroscopic agents as lead subacetate
and glycerine. The remaining three patients had skin
pigmentation which disappeared by the end of the third
month Table 4.
Number of sessions needed for healing: In 25 patients, all
affected venous systems were successfully eradicated following
a single session of UGFS and remained so during follow up. In
15 patients their limbs needed a second session. These patients
needed the second session either due to incomplete eradication
Fig. 2 B-mode ultrasound image of reﬂective needle tip indenting vein wall immediately prior to vein puncture.
Fig. 3 (a) Venous ulcer before sclerotherapy and (b) Venous ulcer after sclerotherapy.
Fig. 4 (a) Big venous ulcer before sclerotherapy and (b) Venous ulcer after sclerotherapy.
802 A.M. Eweda, H. Zaytounof all the incompetent perforators or due to appearance of new
reﬂux during duplex follow up.
No mortality: At all in this study either due to the proce-
dure or during the period of follow up.
Healing and recurrence rates following UGFS were deﬁned
as the time to heal calculated from the date of ﬁrst UGFS
treatment session. Time of recurrence was calculated from
the date of healing of ulcers.
Healing of leg ulcers in the 40 patients under this study was:
At 1, 3, and 6 months after treatment: 5 ulcers (12.5%), 28 ul-cers (70%) and 38 ulcers (95%) respectively had healed com-
pletely, 3 ulcers had recurred (8%) during the follow up
period. Fig. 2, Fig. 3(A and B), Fig. 4(A and B), Fig. 5(A–D).5. Discussion
Although almost all venous ulcers can be treated by simple
conservative measure, in an extensive survey conducted
in 600 patients, 66% had one or more recurrence of venous
Fig. 5 (A) Venous ulcer before sclerotherapy. (B) Duplex of Perforator vein before sclerotherapy. (C) Venous ulcer after sclerotherapy
and (D) Duplex of Perforator vein after sclerotherapy.
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petence caused by primary valvular incompetence or as a se-
quence of deep venous thrombosis, contributes to
ambulatory venous hypertension and the development of
chronic venous disease. Venous leg ulcers are the ultimate
and severest complication of chronic venous insufﬁciency in
patients with post thrombotic syndrome (11). The main goals
when treating patients with leg ulcers associated with chronic
venous insufﬁciency (CVI) are to heal the ulcers as rapidly as
possible, control the patients’ other symptoms manifesting
from their venous disease, and minimizing the potential for
recurrence after healing (12). Recent development of new treat-
ment options for reﬂux in the superﬁcial venous system and
perforators have established a new standard when patients
can be treated in the ofﬁce without a need for general anaesthe-
sia, can ambulate immediately after treatment (13). Injectable
sclerosant has been utilized in the treatment of varicosities for
over a century, with the ﬁrst reported treatment occurring in
1940 (14). The tessari method has evolved into the most pop-
ular of the foaming technique (15). Duplex ultrasound imaging
has increasingly been incorporated into the procedure in order
to establish patency and competence of the deep veins, locate
the incompetent superﬁcial vein to be cannulated, guide cannu-
lation, monitor the injection and ﬂow of foam to minimize the
risk of foam diffusion to the deep venous system (16). Ultra-
sound is also usually used in the follow up period to assess
the results of treatment and determine the need for further
injections (17). Compression is an important part of the treat-
ment to optimize the effect of foam sclerotherapy (18). In
Darvall et al. (2) 27 consecutive patients (28 legs) of median
age 69 years undergoing ultrasound guided foam sclerotherapy
in addition to compression in the treatment of chronic venous
ulcer were prospectively studied. Prior to and at 1, 3, 6 months
after treatment. Median volume of foam used was eight (range
2–14) mL. At 1, 3 and 6 months after UGFS, 22 (79%), 27
(96%) and 27 (96%) chronic venous ulcers had healed. 2(7%) ulcers had recurred, one patient died from carcinomato-
sis (2). The main ﬁnding of Darvall et al. study (2009) (2) is as
follows: following UGFS combined with compression, 27 of 28
(96%) chronic venous ulcers healed within 3 months and only
2 ulcers had recurred later on (2). Pang et al. (18) study was
performed on 130 consecutive patients (132 limbs) of median
age 70 years who underwent UGFS as a part of their treatment
for chronic venous ulcers (18). The main ﬁnding of pang et al.
(2010) (18) study is that when combined with compression,
eradication of superﬁcial venous reﬂux by means of UGFS
leads to 81% healing rate at 6 months and 5% recurrence rate
at 2 years (18). In our study, 40 patients were followed up at 1,
3 and 6 months after treatment 5 ulcers (12.5%), 28 ulcers
(70%) and 38 ulcer (95%), respectively had healed completely,
and 3 ulcers had recurred. The outcomes reported in our study
after UGFS plus compression appear to be superior than those
reported from Ghuari et al. study (2000) (19), where only com-
pression has been used and no attempt has been made to erad-
icate superﬁcial venous reﬂux (healing 68–83% at 6 months,
recurrence 36–28% at 12 months) (19). In Mine et al. study
(2003) (20) a trial of foam sclerotherapy vs. another endove-
nous technique (radio frequency ablation (RFA), endovenous
laser treatment (EVLT) would be possible but may be unnec-
essary (20). Many of the patients in our study would have been
unsuitable for catheter directed techniques and most would
have required adjuvant techniques (foam sclerotherapy). Pa-
tients with chronic venous ulcers have poor healing power,
making incisions through diseased skin is problematic. It
seems reasonable, therefore, to suggest that where possible,
such patients should be treated by minimally invasive alterna-
tive (18).
6. Summary
Chronic venous ulcer is a very common problem in our coun-
try as well as all over the world. Cutaneous venous hyperten-
804 A.M. Eweda, H. Zaytounsion which occurs as a consequence of primary valvular incom-
petence, deep venous obstruction or a combination of both, re-
sults in a series of cutaneous manifestations which in their
most severe forms, result in skin breakdown over the medial
maleolus. Foam sclerotherapy has the advantage of real time
visualization as an effective contrast agent on ultrasound
imaging, allowing manual displacement of the foam into the
selected veins. Additionally the minimally invasive nature of
the procedure permits the patient to return immediately to dai-
ly activities. The present study adds further weight to the sug-
gestion that eradication of superﬁcial venous reﬂux and
incompetent perforators by means of foam sclerotherapy im-
proves venous ulcer outcomes when compared to compression
alone. Foam sclerotherapy is safe and is an effective treatment
of venous ulcer without serious adverse effects. It can be used
for all age groups and all venous systems showing reﬂux.
Conclusion: Foam sclerotherapy is a simple procedure,
compared to surgical intervention, no hospitalization, no
anaesthesia, can be done in out patient clinic and the patient
can return home after 45 min and no work off period. The rel-
ative freedom from serious complications and its evident suc-
cess, make this the ﬁrst line treatment for venous ulcer.
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